^
    Back
    Association details:
    Biomarker:DNMT3A mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:azacitidine (DNA methylation inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancers (Basel)
    Title:

    The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

    Published date:
    05/18/2021
    Excerpt:
    ...newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status...Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis.
    DOI:
    10.3390/cancers13102458
    Trial ID:
    FLUGAZA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    Excerpt:
    ...Acute myeloid leukemia with either Flt-3, TET-2, p53, DNMT3A, or ASXL1 mutation, mutations of genes involved in the chromatin/spliceosome category (EZH2, SRSF2, U2AF1, ZRSR2), BCOR, and RUNX1, as well as MLL rearrangement, EVI1 overexpression in complete morphologic remission; or 3....
    Trial ID:
    NCT02497404
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL

    Published date:
    05/11/2023
    Excerpt:
    In pts with DNMT3Amut/NPM1wildtype AML, mRFS was10.0 vs 4.6 mo for Oral-AZA vs PBO, respectively (HR [CI]: 0.40 [0.225, 0.724]; P=0.002...RFS was improved by Oral-AZA in pts with DNMT3A mutations independent of NPM1 status at Dx.
    Trial ID:
    QUAZAR AML-001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Leuk Lymphoma
    Title:

    Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study

    Published date:
    10/12/2020
    Excerpt:
    CONTRADICTING EVIDENCE: After a median of 5 cycles of AZA, overall response rate was 28% (including 15% complete remission) and median OS was 12.3 months...In multivariate analysis of AML patients, DNMT3A mutation was associated with shorter OS while IDH1/2 mutation subtypes had no independent impact.
    DOI:
    10.1080/10428194.2020.1832661